Breyer, J., Erben, P., & Worst, T. (2018). High CDKN2A/p16 and low FGFR3 expression predict progressive potential of stage pT1 urothelial bladder carcinoma. Clinical genitourinary cancer, 16(4), . https://doi.org/10.1016/j.clgc.2018.01.009
Chicago-Zitierstil (17. Ausg.)Breyer, Johannes, Philipp Erben, und Thomas Worst. "High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage PT1 Urothelial Bladder Carcinoma." Clinical Genitourinary Cancer 16, no. 4 (2018). https://doi.org/10.1016/j.clgc.2018.01.009.
MLA-Zitierstil (9. Ausg.)Breyer, Johannes, et al. "High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage PT1 Urothelial Bladder Carcinoma." Clinical Genitourinary Cancer, vol. 16, no. 4, 2018, https://doi.org/10.1016/j.clgc.2018.01.009.